Eczema in people aged 8 years and older Skin and Connective Tissue Diseases
Conditions
Interventions
INTERVENTION: A 3-part online programme to support management of itch and scratch for people with eczema plus usual care.
CONTROL: Usual eczema care alone.
The intervention is adapted from the ‘Kids
Sponsors
Nottingham University Hospitals NHS Trust
Eligibility
Sex/Gender
All
Age
8 Years to 120 Years
Inclusion criteria
Inclusion criteria: 1. Aged =8 years with self-report of eczema (syn. atopic dermatitis, atopic eczema) 2. Able and willing to participate in the online intervention 3. Usual residence in the UK 4. Able and willing to give informed consent (or parent/legal guardian able and willing to give informed consent for children under 16 years)
Exclusion criteria
Exclusion criteria: 1. Diagnosis unlikely to be atopic eczema: only present on hands (likely to be hand eczema or contact dermatitis); limited to locations where skin is exposed to nickel, e.g. jewellery (likely to be contact dermatitis); eczema only around varicose veins (likely to be varicose eczema) 2. Taking part in another eczema intervention trial 3. Member of household has already agreed to take part in the Scratch Less trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eczema symptoms measured using the Patient Oriented Eczema Measure (POEM) (7 items scored 0 to 28) at baseline and every 4 weeks over 16 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Eczema control measured using the Recap of Atopic Eczema (RECAP) (7 items, scored 0 to 28) at baseline, week 4 and week 16;Itch intensity measured using the Peak Pruritis Numerical Rating Scale (NRS) (one item, scored 0 to 10) at baseline and every 4 weeks over 16 weeks;Scratching over the last week measured using a questionnaire at baseline, week 4 and week 16;Skin-specific quality of life measured using the Children’s Dermatology Life Quality Index (CDLQI) or Dermatology Life Quality Index (DLQI) (10 items, scored 0 to 30) at baseline and week 16;Patient enablement measured using the Patient Enablement Instrument (PEI) at baseline and week 16;Adverse events: measured using a questionnaire which collects: a) Contact with healthcare professional (HCP) because of a worsening of the eczema; b) Open question to capture unexpected events, at week 16;Frequency of skin bleeding due to eczema measured using the Patient Oriented Eczema Measure (POEM) (item 3) at baseline and every 4 weeks over 16 weeks;Proportion of participants who achieve an improvement in POEM of =3 points measured using the Patient Oriented Eczema Measure (POEM) at baseline and week 16 | — |
Countries
England, United Kingdom
Contacts
Public ContactEleanor Harrison
Outcome results
None listed